Spermosens provides update on clinical study progress
Spermosens AB ("Spermosens" or the "Company") is pleased to provide an update on its ongoing clinical study at Reproductive Medicine Center (RMC) in Malmö. This study, which evaluates the diagnostic relevance of the second-generation JUNO-Checked technology, is a significant step toward advancing personalized IVF treatments and supporting sperm banks in identifying the best possible donors. The second-generation JUNO-Checked offers improved performance and a shorter readout time, enhancing the accuracy and efficiency of the analysis.
Now in its sixth week, the study has received strong participation from couples eager to take part. Their involvement has enabled the Company to measure the binding potential of several donor samples using the second-generation JUNO-Checked system. The focus is on assessing the binding capacity of sperm cells to the egg, a critical factor in male fertility diagnostics. In close collaboration with RMC, the data is being correlated with fertilization outcomes to better understand the relationship between sperm binding capacity and successful fertilization. This will ultimately lead to a valuable diagnostic tool for clinicians to personalize treatment and for sperm banks to select high-quality donors.
This study is expected to provide key insights into how JUNO-Checked can personalize fertility treatments by identifying sperm with optimal binding potential, thus improving success rates. Furthermore, JUNO-Checked could help sperm banks qualify donors with the best fertility profiles, enhancing their service quality and outcomes for recipients. These developments will not only position JUNO-Checked as an essential tool in reproductive medicine but also make it attractive to potential partners and future customers seeking advanced, reliable solutions in male infertility diagnostics.
Spermosens remains focused on recruiting additional couples and delivering interim results before the end of 2024. These preliminary results will indicate the potential of JUNO-Checked to address key challenges in male infertility, positioning the technology as a valuable asset for both fertility treatment clinics and sperm banks.
Tore Duvold, CEO of Spermosens, comments:
“The progress we’re seeing reflects the strong support of donors and the excellent collaboration with RMC. By analyzing data from several donor samples, we are taking steps toward validating the second-generation JUNO-Checked’s diagnostic potential. We are excited by the prospect of sharing interim results before year-end, which will not only provide valuable insights into personalized IVF treatments but also increase JUNO-Checked’s appeal to potential partners and customers in the field of male infertility diagnostics.”
Maria Liljander, CSO of Spermosens, adds:
“Our clinical study is progressing well, with robust donor participation and efficient coordination with the RMC team. This is crucial for improving outcomes in fertility treatments, enabling sperm banks to identify donors with the best fertility profiles, and making the technology an increasingly attractive option for potential partners and customers. I look forward to the interim results that will help us validate the technology’s value”
About JUNO-Checked: The second-generation JUNO-Checked is designed to address critical gaps in male infertility diagnostics by assessing the sperm’s capacity to bind to the egg. With improved performance and a shorter readout time, this approach provides deeper insights into sperm function, supports personalized fertility treatments, and enhances the donor selection process for sperm banks, helping couples and institutions achieve better outcomes. The continued development of JUNO-Checked also makes it an increasingly appealing solution for potential partners and future customers in the reproductive medicine and fertility sectors.
Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com
Tags: